Alseres Pharmaceuticals, Inc.
ALSEOTCHealthcare
$0.01
+$0.01(+100.00%)
Market Cap$398255
P/E Ratio—
52W High$0.01
52W Low$0.005
Alseres Pharmaceuticals, Inc. (ALSE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALSE · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2013-12 | 2012-12 | 2011-12 | 2010-12 | 2009-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.47M | $0.53M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.02M | $0.00M | $0.04M | $0.06M | $0.00M |
| Gross Profit | $0.45M | $0.53M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 95.00% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.05M | $0.09M | $0.47M | $3.70M |
| G&A Expenses | $1.42M | $1.67M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $1.04M | $1.74M | $2.06M | $3.12M | $8.33M |
| Operating Income | ($0.97M) | ($1.21M) | ($1.56M) | ($3.12M) | ($8.33M) |
| Operating Margin %(computed) | -204.76% | -228.37% | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.45M | $0.43M | $1.84M | $2.64M | $2.52M |
| Income Before Tax | ($0.94M) | ($1.65M) | ($1.04M) | $3.16M | ($10.78M) |
| Income Tax Expense | $0.00M | $0.00M | $1.32M | ($3.63M) | $0.00M |
| Net Income | ($0.94M) | ($1.65M) | ($2.88M) | $0.51M | ($10.78M) |
| Net Margin %(computed) | -198.85% | -309.96% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-153.67 | $-268.56 | $-486.45 | $50.00 | $-2306.71 |
| Wtd Avg Shares | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| EBITDA | ($0.49M) | ($1.21M) | ($1.00M) | ($9.34M) | ($8.33M) |
| EBITDA Margin %(computed) | -102.59% | -227.99% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Alseres Pharmaceuticals, Inc. data
About Alseres Pharmaceuticals, Inc. (ALSE) Income Statement
Alseres Pharmaceuticals, Inc. (ALSE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2013, ALSE reported revenue of $0.00B, gross profit of $0.00B (gross margin 95.00%), and net income of ($0.00B) — a net profit margin of -198.85%.
Frequently asked questions
ALSE · 4 questionsAlseres Pharmaceuticals, Inc. (ALSE) reported revenue of $0.00B for 2013, down 10.7% year-over-year.
ALSE revenueALSE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09